Manufacturer and distributor of plant-based MiteXstream biopesticide, Black Bird Biotech Inc (OTCMKTS:BBBT), on August 18, 2022, announced entering into a distribution agreement for Grizzly Creek Naturals CBD product line. The agreement has been formed with a national distributor of luxury spa products, Beyond Das Skin.
Trading Data
On Thursday, BBBT stock fell 7.75% to $0.0064 with more than 607K shares, compared to its average volume of 1.39 million shares. The stock moved within a range of $0.0057 – 0.0069 after opening trade at $0.0067.
Black Bird Biotech Signs Distribution Agreement with Chicago-based Distributor of Luxury Spa Products for its Grizzly Creek Naturals(TM) CBD Product Line
In the last four decades of distribution operations, Beyond has established a product distribution network covering Las Vegas, Chicago, New York, Texas, and Florida East Coast.
Owner of Beyond Das Skin owner, Andreas Jungermann, expressed excitement about adding the Grizzly Creek Naturals line to the ever-growing catalog. Andreas added that it fills the void as well as provides high-quality, spa-level products given to clients. Furthermore, Andreas also said that the CBD industry is quickly growing and the firm can make a significant impact.
Fabian Deneault, BBBT’s President said that the company is pleased that Andreas and the Beyond Das Skin team will be using Grizzly Creek Naturals products in the country.
Key Quote
Owner of Beyond Das Skin owner, Andreas Jungermann, said, “I am truly excited to add the Grizzly Creek NaturalsTM line to our ever-growing catalog. It fills our CBD void while providing the same high-quality, spa-level product we take pride in selling to our clients. The CBD industry is a rapidly growing market that we can, and will, make a major impact on. We look forward to distributing for Black Bird Biotech.”
Black Bird Biotech Management Affirms Long-Term Commitment, Exchanges One-Third, over 120 Million, of Outstanding Common Shares for Preferred Shares
Black Bird Biotech on August 15, 2022, announced that the members of the Board of Directors have accepted on exchanging about 124 million shares, or about 36% of its outstanding common stock for shares of a new Series A Preferred Stock.
Fabian Deneault said that the firm has invested four years into MiteXstream Mission and the company will be investing again for establishing it as a globally-recognized game-changing biopesticide.
Technical Data
BBBT stock is trading below the 20-Day and 50-Day Moving averages of $.0061 and $0.0069 respectively. Moreover, the stock is trading below the 200-Day moving average of $0.0122. The company has a total market capitalization of $1.95 million. The stock is down 50% over the past 6-month.
